Mark A. Velleca
2017 - G1 Therapeutics
In 2017, Mark A. Velleca earned a total compensation of $738.2K as Chief Executive Officer and President at G1 Therapeutics, a 45% decrease compared to previous year.
Compensation breakdown
| Bonus | $262,500 |
|---|---|
| Salary | $467,617 |
| Other | $8,100 |
| Total | $738,217 |
Velleca received $467.6K in salary, accounting for 63% of the total pay in 2017.
Velleca also received $262.5K in bonus and $8.1K in other compensation.
Rankings
In 2017, Mark A. Velleca's compensation ranked 10,367th out of 14,666 executives tracked by ExecPay. In other words, Velleca earned more than 29.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,367 out of 14,666 | 29th |
Division Manufacturing | 4,020 out of 5,772 | 30th |
Major group Chemicals And Allied Products | 1,421 out of 2,075 | 32nd |
Industry group Drugs | 1,156 out of 1,731 | 33rd |
Industry Pharmaceutical Preparations | 904 out of 1,333 | 32nd |
Source: SEC filing on April 18, 2018.
Velleca's colleagues
We found three more compensation records of executives who worked with Mark A. Velleca at G1 Therapeutics in 2017.
News
Black Diamond Therapeutics CEO Mark Velleca receives $2.9M in 2023
April 24, 2024
G1 Therapeutics CEO Mark Velleca's 2020 pay stays at $4M
April 28, 2021
G1 Therapeutics Chief Business Officer Mark Avagliano receives $5.5M in 2019
April 24, 2020
G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
April 30, 2019